AR093712A1 - Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento - Google Patents

Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento

Info

Publication number
AR093712A1
AR093712A1 ARP130104466A ARP130104466A AR093712A1 AR 093712 A1 AR093712 A1 AR 093712A1 AR P130104466 A ARP130104466 A AR P130104466A AR P130104466 A ARP130104466 A AR P130104466A AR 093712 A1 AR093712 A1 AR 093712A1
Authority
AR
Argentina
Prior art keywords
vaccine
prevention
procedure
treatment
immunogen composition
Prior art date
Application number
ARP130104466A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR093712A1 publication Critical patent/AR093712A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición inmunógena que comprende: a) Un polipéptido que comprende un fragmento de toxina A de Clostridium difficile aislado y/o un fragmento de toxina B de C. difficile aislado; y b) un coadyuvante que comprende una fracción de saponina inmunológicamente activa presentada en forma de un liposoma.
ARP130104466A 2012-12-05 2013-12-03 Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento AR093712A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05

Publications (1)

Publication Number Publication Date
AR093712A1 true AR093712A1 (es) 2015-06-17

Family

ID=49724573

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104466A AR093712A1 (es) 2012-12-05 2013-12-03 Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento

Country Status (22)

Country Link
US (2) US9694064B2 (es)
EP (2) EP3513806B1 (es)
JP (2) JP6290918B2 (es)
CN (2) CN112807422A (es)
AR (1) AR093712A1 (es)
AU (1) AU2013354186A1 (es)
BR (1) BR112015012841B1 (es)
CA (1) CA2893435A1 (es)
CY (1) CY1121560T1 (es)
DK (2) DK2928489T3 (es)
ES (2) ES2721930T3 (es)
FI (1) FI3513806T3 (es)
HR (2) HRP20230359T1 (es)
HU (2) HUE061273T2 (es)
LT (2) LT3513806T (es)
PL (2) PL3513806T3 (es)
PT (2) PT2928489T (es)
SG (1) SG11201503861UA (es)
SI (2) SI3513806T1 (es)
TR (1) TR201905272T4 (es)
WO (1) WO2014086787A1 (es)
ZA (1) ZA201503927B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130122810A (ko) * 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
EP2753352B2 (en) * 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
FI3513806T3 (fi) * 2012-12-05 2023-04-26 Glaxosmithkline Biologicals Sa Immunogeeninen koostumus
EP3160500B1 (en) * 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
WO2016131157A1 (en) 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CN109311950A (zh) 2016-03-21 2019-02-05 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7149285B2 (ja) 2017-03-15 2022-10-06 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP4168032A2 (en) * 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU709586B2 (en) 1994-10-24 1999-09-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AU781175B2 (en) 1999-04-09 2005-05-12 Intercell Usa, Inc. Recombinant toxin A/toxin B vaccine against Clostridium Difficile
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20100183667A1 (en) * 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
EA201001479A1 (ru) * 2008-04-16 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
EP2753352B2 (en) * 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
SI2714911T1 (sl) * 2011-05-27 2017-03-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
FI3513806T3 (fi) * 2012-12-05 2023-04-26 Glaxosmithkline Biologicals Sa Immunogeeninen koostumus

Also Published As

Publication number Publication date
JP6290918B2 (ja) 2018-03-07
DK3513806T3 (da) 2023-02-27
CY1121560T1 (el) 2020-05-29
PT3513806T (pt) 2023-03-02
SI2928489T1 (sl) 2019-05-31
LT3513806T (lt) 2023-04-11
DK2928489T3 (en) 2019-04-23
JP6626521B2 (ja) 2019-12-25
PL3513806T3 (pl) 2023-05-15
AU2013354186A1 (en) 2014-06-12
US20150313984A1 (en) 2015-11-05
BR112015012841B1 (pt) 2022-05-03
SI3513806T1 (sl) 2023-04-28
FI3513806T3 (fi) 2023-04-26
CN104884081A (zh) 2015-09-02
JP2016502551A (ja) 2016-01-28
HRP20230359T1 (hr) 2023-06-09
ES2939307T3 (es) 2023-04-20
HUE043091T2 (hu) 2019-08-28
JP2018104446A (ja) 2018-07-05
CN112807422A (zh) 2021-05-18
US20170340719A1 (en) 2017-11-30
LT2928489T (lt) 2019-04-10
CA2893435A1 (en) 2014-06-12
ES2721930T3 (es) 2019-08-06
DK3513806T5 (da) 2024-09-02
PT2928489T (pt) 2019-05-28
BR112015012841A2 (pt) 2017-09-26
EP3513806B1 (en) 2023-01-25
US10130694B2 (en) 2018-11-20
TR201905272T4 (tr) 2019-05-21
SG11201503861UA (en) 2015-06-29
PL2928489T3 (pl) 2019-07-31
HRP20190711T1 (hr) 2019-05-31
EP3513806A1 (en) 2019-07-24
EP2928489A1 (en) 2015-10-14
WO2014086787A1 (en) 2014-06-12
US9694064B2 (en) 2017-07-04
HUE061273T2 (hu) 2023-06-28
ZA201503927B (en) 2017-11-29
EP2928489B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AR098256A1 (es) Vectores para expresión de antígenos asociados a próstata
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
CO7111302A2 (es) Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2015001601A (es) Metodos de tratamiento de una tauopatia.
MX2019002968A (es) Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal.
EA201790239A1 (ru) Молекула-носитель для антигенов
NZ718108A (en) Neisseria meningitidis compositions and methods thereof
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
CA2763359C (en) New human rotavirus strains and vaccines
MY191539A (en) Streptococcal vaccine
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
MX2016001695A (es) Composiciones inmunogenas de combinacion.
MY191217A (en) Group a streptococcus vaccine
IN2014CN03454A (es)
BR112015020079A8 (pt) Composições para cuidado oral
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure